FDA Oncology Announcements

STAMP inhibitor × Clear all

2 Announcements

FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia

Drug: Scemblix (asciminib) · STAMP inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia

Drug: Scemblix (asciminib) · STAMP inhibitor
Conditions: MyeloidOther hematologic neoplasm